Idarucizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Dabigatran |
| Clinical data | |
| Trade names | Praxbind |
| ATC code | |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C2131H3299N555O671S11 |
| Molar mass | 47.8 kg/mol g·mol−1 |
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.[1][2]
This drug was developed by Boehringer Ingelheim Pharmaceuticals. A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.[3] It was FDA approved in October 2015.[4] In the United States the wholesale cost is $3500 US.[5]
See also
Other anticoagulant antidotes
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab, American Medical Association.
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ Pollack, Charles V.; Reilly, Paul A.; Eikelboom, John; Glund, Stephan; Verhamme, Peter; Bernstein, Richard A.; Dubiel, Robert; Huisman, Menno V.; Hylek, Elaine M. (2015-08-06). "Idarucizumab for Dabigatran Reversal". The New England Journal of Medicine. 373 (6): 511–520. doi:10.1056/NEJMoa1502000. ISSN 1533-4406. PMID 26095746.
- ^ "Press Announcements - FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa". www.fda.gov. Retrieved 2015-10-17.
- ^ Elia, Joe. "Dabigatran-Reversal Agent Price Set". Retrieved 20 October 2015.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |